This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT00770965
First received: October 9, 2008
Last updated: March 30, 2015
Last verified: March 2015
  Purpose
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either AIN457 at one of the three doses studied or placebo.

Condition Intervention Phase
Chronic Plaque Psoriasis Biological: AIN457 Biological: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Single Dose, Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Study to Assess the Efficacy of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis

Resource links provided by NLM:


Further study details as provided by Novartis ( Novartis Pharmaceuticals ):

Primary Outcome Measures:
  • Change From Baseline in Psoriasis Area and Severity Index (PASI) Scores [ Time Frame: baseline, week 4 ]
    This study was not powered for efficacy. Due to audit findings at one site, which included 65 participants, all participants enrolled at the site were excluded from the planned efficacy analyses. As a result, efficacy could not be analyzed due to an insufficient number of participants.


Secondary Outcome Measures:
  • Change From Baseline in PASI [ Time Frame: baseline, weeks 12, 14, 16, 20, 24, 28 and 32 ]
    This study was not powered for efficacy. Due to audit findings at one site, which included 65 participants, all participants enrolled at site were excluded from the planned efficacy analyses. As a result, efficacy could not be analyzed due to an insufficient number of participants.

  • Investigator Global Assessment (IGA) Scores [ Time Frame: baseline, day 1, weeks 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 32 ]
    This study was not powered for efficacy. Due to audit findings at one site, which included 65 participants, all participants enrolled at the site were excluded from the planned efficacy analyses. As a result, efficacy could not be analyzed due to an insufficient number of participants.


Enrollment: 80
Study Start Date: September 2008
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AIN457 0.3 mg/kg
Participants received AIN457 0.3 mg/kg IV on Day 1.
Biological: AIN457
Experimental: AIN457 1.0 mg/kg
Participants received AIN457 1.0 mg/kg IV on Day 1.
Biological: AIN457
Experimental: AIN457 3.0 mg/kg
Participants received AIN457 3.0 mg/kg IV on Day 1.
Biological: AIN457
Placebo Comparator: Placebo
Participants received placebo to AIN457A IV on day 1.
Biological: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of plaque psoriasis for at least 6 months prior to screening. The patients must meet all of the following criterion:

    1. Coverage of the body surface area (BSA) of 10% or more with plaques
    2. A score of 3 or more on the IGA (Investigator Global Assessment) scale
    3. A PASI score of at least 12 at baseline;

      Exclusion Criteria:

  • Have forms of psoriasis other than the required "plaque psoriasis"
  • Women of childbearing potential
  • Recent use of investigational drugs or treatment with other biological therapies (wash-out periods required)
  • Previous treatment with this investigational drug
  • Subjects with active or history of clinically significant cardiac, kidney or liver abnormalities

Other protocol-defined inclusion/exclusion criteria may have applied.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00770965

Locations
United States, California
Novartis Investigative Site
Santa Monica, California, United States, 90404
United States, Kentucky
Novartis Investigative Site
Louisville, Kentucky, United States, 40217
United States, North Carolina
Novartis Investigative Site
High Point, North Carolina, United States, 27262
United States, Pennsylvania
Novartis Investigative Site
Duncansville, Pennsylvania, United States, 16634
United States, Tennessee
Novartis Investigative Site
Nashville, Tennessee, United States, 37215
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Principal Investigator: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00770965     History of Changes
Other Study ID Numbers: CAIN457A2204
Study First Received: October 9, 2008
Results First Received: February 2, 2015
Last Updated: March 30, 2015

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Plaque psoriasis, skin condition, thickening, flaking, skin disease, autoimmune disease

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases

ClinicalTrials.gov processed this record on August 22, 2017